CSL Draws a Line Under Vifor Era as Cost Cuts Fund the Next Growth Push

CSL absorbed $7.1B in pre-tax impairments, mostly on Vifor, as group revenue slipped 1% to $15.8B and Vifor faces a 25% sales drop.

CSL is steering its business toward consolidation in the current fiscal year, following the multibillion-dollar write-downs that reshaped its balance sheet and forced a hard look at the 2022 acquisition of CSL Vifor.

The Australian biotech group absorbed pre-tax impairments of 7.1 billion US dollars over the year to the end of June 2026, with the bulk of that charge landing on Vifor. The timing was heavily skewed to the second half, which accounted for 5.5 billion US dollars of the total. Restructuring costs of 799 million US dollars piled on top.

Tamim Asset Management attributes the lion's share of the impairment to the Vifor unit, which specializes in iron deficiency and kidney disease. The business is contending with generic competition and the expiry of US reimbursement advantages for dialysis treatments — a combination that points to a revenue decline of roughly a quarter for the segment.

Revenue slips as Behring holds the line

Group revenue for the fiscal year eased 1 percent to 15.8 billion US dollars. CSL Behring, the plasma business, generated 11.4 billion US dollars of that total. Vifor contributed 2.4 billion US dollars and the vaccine arm Seqirus 2.0 billion US dollars. Underlying net profit (NOPAT) retreated 2 percent to about 3.1 billion US dollars.

Behring has proven the more resilient engine. Immunoglobulin sales returned to growth in the second half after US Medicare adjustments and a destocking phase worked through the system. A new immunoglobulin plant came on stream in Kankakee, Illinois, while cost per liter of plasma fell on the back of efficiency measures and site closures.

Management is guiding for broadly flat group revenue at constant currencies in the current year, alongside moderate growth in underlying profit. Behring is expected to post modest expansion, helped by the second-half recovery in immunoglobulin demand. Vifor, by contrast, is forecast to shed around 25 percent of its revenue.

Savings overshoot funds the growth agenda

To offset that drag, CSL is sharpening its savings program. Having already beaten its original target, the company raised the bar for both the current and the coming year. Roughly half of the additional savings will be channeled directly into growth initiatives, including sales expansion in the US and China and clinical development. A further 1.5 billion US dollars has been earmarked for US plasma manufacturing.

Free cash is also flowing back to shareholders. The on-market buyback, which runs until 30 June 2027, carries a total volume of up to 1.15 billion Australian dollars.

Leadership and Seqirus questions linger

Two strategic loose ends remain for investors. The CEO position is still unfilled, with Gordon Naylor holding the reins on an interim basis. And the spin-off of Seqirus — originally envisaged for the past fiscal year — has yet to be resolved.

Attention now turns to the autumn corporate calendar, where a business update is expected to shed light on progress in filling the top job and on the future of the vaccine unit. Detailed half-year figures will follow in February 2027.

The stock closed at 109.42 euros in the previous session, a daily decline of 2.1 percent, and has gained 10 percent since the start of the year.